Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease

Figure 1 Modifiers of the natural course of metabolic dysfunction-associated steatotic liver disease. Schematic illustration of multiple factors [schematically depicted in the upper line clockwise: (1) Age; (2) Ethnicity; (3) Lifestyle; (4) Genetics; (5) Obesity; (6) Diabetes; and (7) Medications] which, further to the fundamental components of metabolic dysfunction-associated steatotic liver disease (MASLD) histology [shown in the bottom-line, from left to right: (1) Steatosis; (2) Steatohepatitis; and (3) Cirrhosis], can potentially modulate the natural course of MASLD and the odds of decompensation of MASLD-related compensated advanced chronic liver disease. MASLD: Metabolic dysfunction-associated steatotic liver disease.